Shots:

• Parvus to receive an upfront & milestones exceeding $800M and royalties on sales of products targeting for IBD- ALD & Celiac diseases- and will conduct pre/clinical studies till P-I study. Additionally- will also obtain milestones & royalties on sales of products for other therapy areas
• Roche to get WW license to develop and commercialize therapies utilizing Parvus’ Navacims platform for autoimmune disorders and will be responsible for their development post-P-I studies in addition to their regulatory submission
• Parvus’ Navacims are precision medicine platform for autoimmune diseases by inducing immune tolerance without generalized immune suppression and targets disease pertinent TCR which restores the immune system balance

Ref: Parvus Therapeutics | Image: Roche